News and updates from IPOX®, including media mentions, interviews, research and press releases.
IPOX® Research Associate Dr. Lukas Muehlbauer commented on the U.S. IPO filing of Australian meat producer Kilcoy Global Foods. The article discusses the recent resurgence in the U.S. IPO market and notes that Kilcoy's listing will be a significant indicator of investor appetite for companies with intricate global supply chains.
In a Reuters article covering Chime’s IPO, IPOX® VP Kat Liu, provided expert commentary on the implications of the company’s strong market reception. Ms. Liu noted that the performance of a high-profile "unicorn" like Chime is being closely watched and could encourage other private fintech companies to move forward with their own public offerings.
In a Reuters article covering the successful market debut of Voyager Technologies, IPOX® Associate Lukas Muehlbauer was quoted in the piece, stating, "Strategic government backing amid increased defense spending somewhat shields these [defense] firms from tariff-induced supply chain risks." His analysis underscores the unique factors contributing to the resilience and attractiveness of companies within the sector.
In a recent Bloomberg article, IPOX® Founder Josef Schuster provided his expert commentary on the U.S. IPO market's recent surge in performance. He described a "positive feedback loop" where unsatisfied demand for one hot listing is driving investor orders for the next, contributing to the market's momentum. Schuster noted that while this enthusiasm is promising, the true test for the recovery will be the fundamental strength shown in the first quarterly earnings from these newly public companies, stating, "When you see the first set of earnings from some of these companies, you will really see how substantial this recovery of the IPO market is going to be."
In a recent Reuters article, IPOX® VP Kat Liu, provided commentary on the upcoming IPO of property insurance technology company Slide. The company is reportedly targeting a valuation of up to $2.12 billion and aims to raise as much as $340 million.
In a recent report by Reuters, IPOX® Research Associate Dr. Lukas Muehlbauer provided commentary on the upcoming U.S. initial public offering of cancer diagnostic firm Caris Life Sciences . The company is aiming for a valuation of up to $5.3 billion, seeking to raise as much as $423.5 million.
In a Reuters report on Circle's successful market debut, IPOX® Research Associate Lukas Muehlbauer offered context on the strengthening IPO pipeline. He observed that the most successful recent listings have been from firms in resilient industries, stating they were "largely by companies less exposed to international supply chain risks" and that the trend would likely continue for sectors such as AI, defense, or fintech.
In a Reuters feature on Gemini's recent IPO filing, IPOX® Vice President Kat Liu commented on the growing trend of digital asset firms going public. Liu explained that this move signals a readiness from long-anticipated firms to re-engage with public capital. She noted, "investor appetite is returning, especially for companies with well-defined business models in strategic sectors such as fintech, AI and digital assets," highlighting the renewed market vigor for such offerings.
In a recent Bloomberg article, IPOX® Founder Josef Schuster provided his expert commentary on the U.S. IPO market's striking resilience despite recent volatility. He noted the market's ability to withstand bond market pressures, highlighting that strong performers like CoreWeave are boosting investor confidence. Schuster observed that "risk appetite is rising for certain deals," indicating potential for continued positive momentum given solid company fundamentals and performance.